Comparative Pharmacology
Head-to-head clinical analysis: ASPIRIN versus PRASUGREL HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASPIRIN versus PRASUGREL HYDROCHLORIDE.
Aspirin vs PRASUGREL HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Irreversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) via acetylation, reducing prostaglandin and thromboxane A2 synthesis. Also activates lipoxin biosynthesis (inflammation resolution).
Prasugrel is an irreversible antagonist of the P2Y12 receptor on platelets, inhibiting ADP-mediated platelet aggregation.
325-650 mg PO q4-6h prn; max 4 g/day
Loading dose: 60 mg orally once. Maintenance: 10 mg orally once daily. Administered with aspirin 75-100 mg daily.
None Documented
None Documented
30 minutes for aspirin (parent drug); salicylic acid: 2-3 hours after low doses, 15-30 hours after high doses due to saturable metabolism and renal reabsorption. Clinical context: prolonged half-life in overdose, renal impairment, and elderly patients.
The terminal elimination half-life of the active metabolite is approximately 7 hours (range 2–15 hours). Clinical context: Once-daily dosing achieves sufficient antiplatelet effect due to irreversible P2Y12 receptor binding; recovery of platelet function occurs over 5–7 days.
Renal excretion of salicylates (75-85% as salicyluric acid, 10% as free salicylic acid, 5-10% as glucuronide conjugates); dose-dependent, with renal clearance decreasing at higher doses due to saturation of metabolic pathways. Biliary/fecal elimination is minimal (<5%).
Approximately 68% of the administered dose is eliminated in urine (as inactive metabolites) and 27% in feces. Less than 1% is excreted as unchanged parent drug.
Category C
Category A/B
NSAID / Antiplatelet
Antiplatelet